Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia
暂无分享,去创建一个
L. Mehlum | E. Johnsen | R. Kroken | L. Mellesdal | M. F. Strømme | M. Krogenes | Christoffer Bartz-Johannesen
[1] L. Mehlum,et al. Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study , 2021, Schizophrenia Research.
[2] A. Tanskanen,et al. Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia , 2020, European Journal of Clinical Pharmacology.
[3] L. Baandrup. Polypharmacy in schizophrenia. , 2020, Basic & clinical pharmacology & toxicology.
[4] Masaru Mimura,et al. Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms , 2019, Schizophrenia Research.
[5] M. Olfson,et al. Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia , 2019, JAMA psychiatry.
[6] S. Uysal. ICD-10-CM Diagnosis Coding for Neuropsychological Assessment. , 2018, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[7] C. Correll,et al. What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia? , 2018, World psychiatry : official journal of the World Psychiatric Association.
[8] I. Laszlovszky,et al. Negative Symptoms of Schizophrenia: Constructs, Burden, and Management , 2018, Psychotic Disorders - An Update.
[9] A. Tanskanen,et al. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up , 2017, Schizophrenia bulletin.
[10] A. Tanskanen,et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia , 2017, JAMA psychiatry.
[11] Takeshi Inoue,et al. Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study , 2016, Neuropsychiatric disease and treatment.
[12] S. Leucht,et al. Valproate for schizophrenia. , 2016, The Cochrane database of systematic reviews.
[13] K. Chen,et al. The readmission rate and medical cost of patients with schizophrenia after first hospitalization — A 10-year follow-up population-based study , 2016, Schizophrenia Research.
[14] S. Leucht,et al. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials , 2013, European Neuropsychopharmacology.
[15] T. Stroup,et al. Polypharmacy for schizophrenia , 2013, Current opinion in psychiatry.
[16] H. Jørgensen,et al. Time-dependent effect analysis of antipsychotic treatment in a naturalistic cohort study of patients with schizophrenia , 2012, European Psychiatry.
[17] John M. Davis,et al. Maintenance treatment with antipsychotic drugs for schizophrenia. , 2012, The Cochrane database of systematic reviews.
[18] Sarah E Hetrick,et al. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. , 2011, Schizophrenia bulletin.
[19] M. Keshavan,et al. Schizophrenia, “just the facts” 4. Clinical features and conceptualization , 2009, Schizophrenia Research.
[20] J. Bartko,et al. Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use , 2008, PloS one.
[21] C. Mullins,et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia , 2008, Schizophrenia Research.
[22] J. Kane,et al. Methodological issues in current antipsychotic drug trials. , 2007, Schizophrenia bulletin.
[23] S. Leucht,et al. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. , 2006, The Journal of clinical psychiatry.
[24] P. Masand,et al. Polypharmacy in schizophrenia , 2006, International journal of psychiatry in clinical practice.
[25] L. Teplin,et al. Crime victimization in adults with severe mental illness: comparison with the National Crime Victimization Survey. , 2005, Archives of general psychiatry.
[26] M. Knapp,et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life , 2004, British Journal of Psychiatry.
[27] R. Kahn,et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. , 2002, Archives of general psychiatry.
[28] J. Stephenson. Delay in treating schizophrenia may narrow therapeutic window of opportunity. , 2000, JAMA.
[29] W. H. Wilson. Lithium in schizophrenia. , 1986, Hospital & community psychiatry.
[30] R. Greenstein,et al. Benzodiazepines in schizophrenia. , 1986, Psychosomatics.
[31] A. Włodarczyk,et al. Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. , 2017, Psychiatria Danubina.
[32] V. Janout,et al. Epidemiology and risk factors of schizophrenia. , 2016, Neuro endocrinology letters.
[33] E. Gambrill. Evidence-based practice in the field of substance abuse: a book of readings. , 2010 .
[34] D. Daniel,et al. Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia , 2003, Neuropsychopharmacology.
[35] R Giel,et al. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. , 1998, Schizophrenia bulletin.
[36] R. Drake,et al. Assessing substance use disorder in persons with severe mental illness. , 1996, New directions for mental health services.